Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Movers and Shakers

- PMLiVE

Pfizer and Otsuka face drug rejections in Europe

EMA turns down Xeljanz for rheumatoid arthritis and delamanid for tuberculosis

UK flag

London plans ‘Med City’ to boost UK life sciences sector

£1.1m investment will bring London, Oxford and Cambridge together in 'golden triangle' of research

CytomX makes senior changes following Pfizer deal

Krishna Polu joins as chief medical officer and Debanjan Ray promoted to VP, business development

- PMLiVE

UK appoints chief inspector of adult social care

Andrea Sutcliffe to improve way the CQC regulates social care

- PMLiVE

Pfizer wins Xeljanz approvals in five more countries

Switzerland, Argentina, Kuwait, United Arab Emirates and Russia to receive arthritis drug

- PMLiVE

AstraZeneca launches Nexium YouTube channel

New AZPurpleZone channel aimed at US patients with acid reflux disease offers symptom-relief advice and product savings

National Institute for Health and Care Excellence NICE logo

Pfizer faces NICE rejection for cancer drug Bosulif

Draft guidance says drug is not cost-effective in chronic myeloid leukaemia

- PMLiVE

FDA looks at new use for BMS/Pfizer’s Eliquis

Could provide a welcome new indication for the anticoagulant

- PMLiVE

Pfizer expands Xeljanz manufacturing capability in Ireland

Invests $130m in manufacturing in Dublin and Cork

- PMLiVE

Pfizer wins new European approval for Prevenar 13

Expands use of pneumococcal disease vaccine to cover people aged 18 to 49

- PMLiVE

Interview: David Haslam, NICE

The new chair of the UK’s NICE discusses navigating the stormy waters of health service reforms, collaborating with pharma and the introduction of VBP

UK flag

UK plans to cut some drug prices by up to 20 per cent

DH proposal relates to medicines not covered by PPRS

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links